Are Simple Cysts Found on Ultrasound Exams Linked to Ovarian Cancer?


This study was the first in a large, unselected population to assess ovarian mass appearance and the connection to ovarian cancer risk.

A large case-control study found that ultrasonographic appearance of ovarian masses is significantly associated with the risk of ovarian cancer. The presence of simple cysts was not associated with any increased risk, while complex cysts and solid masses are correlated with a higher risk of cancer.

“Increased use of transvaginal pelvic ultrasonography has led to the frequent identification of ovarian masses,” wrote study authors led by Rebecca Smith-Bindman, MD, of the University of California, San Francisco. Simple cysts are the most commonly such masses identified, and in spite of evidence suggesting these are likely not cancer precursors, guidelines and researchers continue to recommend ongoing surveillance. “The recommendations for ongoing surveillance of simple cysts, despite widespread belief that they are almost certainly benign, in part reflects the poor prognosis of malignant ovarian cancer and concern that there is a small but unknown risk of cancer even in masses with the most benign appearances.”

The new study was the first in a large, unselected population to assess ovarian mass appearance and the connection to ovarian cancer risk. It was a nested case-control study of patients enrolled in Kaiser Permanente Washington, a large healthcare system in Washington State, and included a total of 72,093 women who underwent pelvic ultrasonography examinations over a 10-year period. The results were published in JAMA Internal Medicine.

A total of 210 women were subsequently diagnosed with ovarian cancer. In the full cohort, 75.5% of women were younger than 50 years, while 76.7% of those with ovarian cancer were 50 years and older. The diagnosis of ovarian cancer occurred a mean of 3.4 months following the first ultrasonography.

Simple cysts were the most common ovarian finding, occurring in 23.8% of the cohort aged younger than 50 years and in 13.4% of those aged 50 years and older. Among the 15,306 women with a simple cyst, only one woman was subsequently diagnosed with ovarian cancer within 3 years; this results in a likelihood ratio of an ovarian cancer diagnosis after a simple cyst of 0.06 (95% CI, 0.01–0.48).

Among women diagnosed with ovarian cancer, the most common finding was a complex cystic mass; this was found in 31 of 49 women (63.3%) younger than 50 years, and in 90 of 161 women (55.9%) 50 years and older. Finding a complex cystic mass on ultrasonography raised the risk of ovarian cancer significantly in both women younger than 50 years, with a likelihood ratio of 8.20 (95% CI, 4.21–15.90), and in those 50 years and older, with a likelihood ratio of 7.60 (95% CI, 5.00–11.59).

Solid masses occurred in 10.2% of those with ovarian cancer younger than 50 years, and in 7.5% of those 50 years and older. Again, the finding of a solid mass was associated with increased risk of ovarian cancer, with a likelihood ratio of 8.08 (95% CI, 1.86–36.12) in younger women and of 10.08 (95% CI, 3.25–31.21) in older women.

On a multivariable analysis, ultrasonography findings were significant predictors of cancer (C statistic, 0.89), and both complex cysts and solid masses were associated with increased risk. Women with normal ovaries, with simple cysts, and with cysts with low-level echoes were all not associated with any increased risk.

In an accompanying editorial, Deborah Levine, MD, of Beth Israel Deaconess Medical Center in Boston, pointed out several methodological limitations of the study, including an inability to account for patient symptoms, which can guide treatment, and the small number of ultrasounds actually evaluated out of the larger cohort. Still, she agreed that the findings regarding simple cysts are important.

“The results ... add to the growing literature that asymptomatic simple cysts may be safely ignored, regardless of size and regardless of patient age,” Levine wrote. “With confident diagnosis of simple cysts, clinicians can be reassured that the likelihood of cancer is similar to that of patients without cysts, and management can be based on patient symptoms rather than on a benign incidental pelvic ultrasonographic finding.”

Related Videos
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
In addition to potentially moving mirvetuximab into earlier lines of treatment for those with platinum-sensitive ovarian cancer, Ritu Salani, MD, also discusses combining the agent with carboplatin to decrease toxicities and improve quality of life.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
Related Content